Physician profile
Michael James Stagner
NPI 1720069982
$987.03
in general payments reported to CMS, 2019-2025
14 companies · $228 in 2025
The $228 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.44 · 2021: $26.72 · 2022: $72.79 · 2023: $181 · 2024: $466 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $875.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $146.95 | 2021-2025 | Rocklatan, Tryptyr, Clareon |
| Amgen INC. | $137.55 | 2024-2025 | Tepezza |
| Abbvie INC. | $134.24 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $122.62 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Rxsight INC | $109.31 | 2024 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal) |
| Sun Pharmaceutical Industries INC. | $108.83 | 2020-2023 | Cequa, Bromsite, Xelpros |
| Dompe US, INC. | $54.74 | 2024-2025 | Oxervate |
| Oyster Point Pharma, INC. | $43.26 | 2023-2024 | Tyrvaya |
| Biotissue Holdings INC. | $38.05 | 2025 | |
| Apellis Pharmaceuticals, INC. | $28.64 | 2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $18.89 | 2023 | |
| Horizon Therapeutics Plc | $18.60 | 2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $13.28 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.